FAQ/Help |
Calendar |
Search |
Today's Posts |
10-06-2016, 10:41 AM | #1 | ||
|
|||
Member
|
This is really heating up!
According to an Inhibikase Therapeutics media release, the Investigational New Drug (IND) application filed by the company has received FDA clearance to initiate this clinical trial and should begin patient evaluation for enrollment within a few months. A double-blind, placebo-controlled clinical study of Nilotinib (Tasigna(R)) in patients with Parkinson's disease - AdisInsight |
||
Reply With Quote |
|
|
Similar Threads | ||||
Thread | Forum | |||
Michael Fox Partners to Assess Clinical Development of Nilotinib in Parkinson's | Parkinson's Disease | |||
Randomized, double-blind, placebo-controlled pilot trial of reduced coenzyme Q10 for | Parkinson's Disease | |||
Randomized, double-blind, placebo-controlled pilot trial of reduced coenzyme Q10 for | Parkinson's Disease | |||
Double blind Duodopa study abstract | Parkinson's Disease | |||
Double blind study of Stalevo vs Sinemet | Parkinson's Disease |